CARE Research Newsletter: Featuring 3 New Projects
Inviragen Initiates a Phase 2 Clinical Study
Inviragen, Inc (Fort Collins) announced the initiation of a Phase 2, randomized, double-blind, placebo-controlled study of DENVax, the Company’s investigational dengue vaccine. The Phase 2 trial will test the safety and immunogenicity of DENVax in multiple age groups in dengue endemic countries. The initiation of this Phase 2 study follows the successful conclusion of a Phase 1 study of DENVax that was conducted in Colombia in collaboration with PECET, the Program for the Study and Control of Tropical Diseases at Universidad de Antioquia. Data from this Phase 1 study demonstrate that the vaccine is safe and well-tolerated and immunogenic in dengue-naive adults; the results will be presented at the annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) on December 7, 2011 in Philadelphia, PA. http://www.businesswire.com/news/home/20111128005344/en/Inviragen-Initiates-Phase-2-Clinical-Study-DENVax
Mitchell elected President of the American Association of Pharmaceutical Scientists
David Y. Mitchell, Ph.D., president and owner of Mitchell Pharmaceutical Consulting, LLC, based in Lafayette, Colorado, has been elected to serve as President of the American Association of Pharmaceutical Scientists (AAPS), a member-based organization of approximately 12,000 located in Arlington, Va. He began his term on the AAPS Executive Council as President in October at the 2011 AAPS Annual Meeting and Exposition in Washington, DC. The meeting included more than 8,500 pharmaceutical scientists from around the world.
Colorado biotech developing agent to track heart disease
CENTENNIAL - Each year, about 1.2 million people in the United States have heart attacks.
ARCA Biopharma: Data Show Lead Drug Reduced Arrhythmia Risk
ARCA biopharma Inc. (ABIO) said late-stage trial data of its lead investigational drug showed it decreased the risk of new heart arrhythmia in a class of heart-failure patient.
Clovis Oncology IPO raises $130 million
Denver Business Journal
Clovis Oncology Inc. raised $130 million through the sale of 10 million shares in the biotech’s initial public offering Wednesday.
Bennet Urges FDA to Provide More Regulatory Certainty to Spark Investments in Colorado Medical Device Industry
Promotes Cutting Red Tape While Ensuring Patients' Access to Safe and Effective Devices
Creation Technologies acquires Quest Product Development Corp
Creation Technologies Enhances Design Services Offering
Manufacturer acquires the design, product development and manufacturing group
of Quest Product Development Corp.
PharmaJet Receives Grand Challenges Explorations Funding
PharmaJet, Inc. announced today that it will receive funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables researchers worldwide to pursue innovations that address persistent health and development challenges.
Fitzsimons Redevelopment Strategic Refocus and Bioscience Industry Board Additions
Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in the Bioscience Industry to Its Board